Selective COX-2 inhibitors and risk of myocardial infarction

Journal of Vascular Research

Volumn 42, Issue 4, 2005, Pages 312-324

  Krötz, Florian ^a   Schiele, Thomas M ^a   Klauss, Volker ^a   Sohn, Hae Young ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atherothrombosis; Cyclooxygenase; Cyclooxygenase 2; NSAID; Platelets

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTACYCLIN; PROSTAGLANDIN; PROSTANOID; ROFECOXIB; VALDECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUSTRY; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEALTH PRACTITIONER; HEART INFARCTION; HUMAN; INFLAMMATION; KIDNEY; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD VESSELS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; EPOPROSTENOL; HUMANS; MEMBRANE PROTEINS; MYOCARDIAL INFARCTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOSIS; THROMBOXANE A2;

EID: 23844551911     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086459     Document Type: Review

References (96)

1. Topol EJ: Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-1709.
2. Josefson D: FDA warns Merck over its promotion of rofecoxib. BMJ 2001;323:767.
3. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP: Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004;177:235-243.
4. Warner TD, Mitchell JA: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804.
5. Davidge ST: Prostaglandin H synthase and vascular function. Circ Res 2001;89:650-660.
6. FitzGerald GA: COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-890.
7. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-182.
8. Chandrasekharan NV, Dai H, Roos KL, et al: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926-13931.
9. Schwab JM, Schluesener HJ, Laufer S: COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003;361:981-982.
10. Helliwell RJ, Adams LF, Mitchell MD: Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids 2004;70:101-113.
11. FitzGerald GA: Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991;68:11B-15B.
12. Armstrong RA: Platelet prostanoid receptors. Pharmacol Ther 1996;72:171-191.
13. Patrono C, Coller B, Dalen JE, et al: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:39S-63S.
14. Patrono C, Patrignani P, Garcia Rodriguez LA: Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001;108:7-13.
15. Crofford LJ, Oates JC, McCune WJ, et al: Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum 2000;43:1891-1896.
16. Capone ML, Tacconelli S, Sciulli MG, et al: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-1471.
17. Lipsky PE: Role of cyclooxygenase-1 and -2 in health and disease. Am J Orthop 1999;28:8-12.
18. Buttar NS, Wang KK: The 'aspirin' of the new millennium: cyclooxygenase-2 inhibitors. Mayo Clin Proc 2000;75:1027-1038.
19. Hinz B, Brune K, Pahl A: Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E(2), and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun 2000;278:790-796.
20. Hinz B, Brune K: Cyclooxygenase-2 - 10 years later. J Pharmacol Exp Ther 2002;300:367-375.
21. Zimmermann KC, Sarbia M, Schror K, Weber AA: Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998;54:536-540.
22. Iseki S: Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach. Histochem J 1995;27:323-328.
23. Nantel F, Meadows E, Denis D, Connolly B, Metters KM, Giaid A: Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999;457:475-477.
24. Chakraborty I, Das SK, Wang J, Dey SK: Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996;16:107-122.
25. Slater DM, Dennes WJ, Campa JS, Poston L, Bennett PR: Expression of cyclo-oxygenase types-1 and -2 in human myometrium throughout pregnancy. Mol Hum Reprod 1999;5:880-884.
26. Slater D, Dennes W, Sawdy R, Allport V, Bennett P: Expression of cyclo-oxygenase types-1 and -2 in human fetal membranes throughout pregnancy. J Mol Endocrinol 1999;22:125-130.
27. Damm J, Rau T, Maihofner C, Pahl A, Brune K: Constitutive expression and localization of COX-1 and COX-2 in rabbit iris and ciliary body. Exp Eye Res 2001;72:611-621.
28. Tegeder I, Neupert W, Guhring H, Geisslinger G: Effects of selective and unselective cyclooxygenase inhibitors on prostanoid release from various rat organs. J Pharmacol Exp Ther 2000;292:1161-1168.
29. Parente L, Perretti M: Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003;65:153-159.
30. Murphy JF, Steele C, Belton O, Fitzgerald DJ: Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3. Br J Haematol 2003;121:157-164.
31. Liou JY, Shyue SK, Tsai MJ, Chung CL, Chu KY, Wu KK: Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothehal cells. J Biol Chem 2000;275:15314-15320.
32. Camacho M, Lopez-Belmonte J, Vila L: Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ Res 1998;83:353-365.
33. Wright DH, Abran D, Bhattacharya M, et al: Prostanoid receptors: ontogeny and implications in vascular physiology. Am J Physiol Regul Integr Comp Physiol 2001;281:R1343-R1360.
34. Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B: Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999;21:943-953.
35. Reicin A, Brown J, Jove M, et al: Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am J Orthop 2001;30:40-48.
36. Cannon GW, Caldwell JR, Holt P, et al: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43:978-987.
37. Day R, Morrison B, Luza A, et al: A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000;160:1781-1787.
38. Simon LS, Lanza FL, Lipsky PE, et al: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-1602.
39. Laine L, Harper S, Simon T, et al: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-783.
40. Bombardier C, Laine L, Reicin A, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
41. Silverstein FE, Faich G, Goldstein JL, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000;284:1247-1255.
42. FitzGerald GA: Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003;361:542-544.
43. Riendeau D, Percival MD, Brideau C, et al: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558-566.
44. Brune K, Hinz B: Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004;33:1-6.
45. Lyseng-Williamson KA, Curran MP: Lumiracoxib. Drugs 2004;64:2237-2246.
46. Catella-Lawson F, McAdam B, Morrison BW, et al: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-741.
47. Leese PT, Recker DP, Kent JD: The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 2003;43:504-513.
48. Leese PT, Talwalker S, Kent JD, Recker DP: Valdecoxib does not impair platelet function. Am J Emerg Med 2002;20:275-281.
49. Stichtenoth DO: The second generation of COX-2 inhibitors: clinical pharmacological point of view. Mini Rev Med Chem 2004;4:617-624.
50. Garnett WR: Clinical implications of drug interactions with coxibs. Pharmacotherapy 2001;21:1223-1232.
51. Krotz F, Riexinger T, Buerkle MA, et al: Membrane potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol 2004;24:595-600.
52. Hoepfl B, Rodenwaldt B, Pohl U, De Wit C: EDHF, but not NO or prostaglandins, is critical to evoke a conducted dilation upon ACh in hamster arterioles. Am J Physiol Heart Circ Physiol 2002;283:H996-H1004.
53. Schnitzer TJ, Burmester GR, Mysler E, et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-674.
54. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM: Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002;14:1101-1111.
55. Hunt RH, Harper S, Watson DJ, et al: The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725-1733.
56. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-277.
57. Buerkle MA, Lehrer S, Sohn HY, Conzen P, Pohl U, Krotz F: Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 2004;110:2053-2059.
58. 2 formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004;43:526-531.
59. Belton OA, Duffy A, Toomey S, Fitzgerald DJ: Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 2003;108:3017-3023.
60. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ: Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000;102:840-845.
61. Qi Z, Hao CM, Langenbach RI, et al: Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002;110:61-69.
62. McAdam BF, Mardini IA, Habib A, et al: Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000;105:1473-1482.
63. Widlansky ME, Price DT, Gokce N, et al: Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003;42:310-315.
64. Llinas MT, Lopez R, Rodriguez F, Roig F, Salazar FJ: Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol 2001;281:F975-F982.
65. Pidgeon GP, Tamosiuniene R, Chen G, et al: Intravascular thrombosis after hypoxia-induced pulmonary hypertension: Regulation by cyclooxygenase-2. Circulation 2004;110:2701-2707.
66. Burleigh ME, Babaev VR, Oates JA, et al: Cyclooxygenase-2 promotes early atherosclerotic lesion formation ill LDL receptor-deficient mice. Circulation 2002;105:1816-1823.
67. Heymes C, Habib A, Yang D, et al: Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. Br J Pharmacol 2000;131:804-810.
68. Chenevard R, Hurlimann D, Bechir M, et al: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-409.
69. Bogaty P, Brophy JM, Noel M, et al: Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 2004;110:934-939.
70. Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA: Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003;42:1747-1753.
71. Bea F, Blessing E, Bennett BJ, et al: Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 2003;60:198-204.
72. Li X, Geary GG, Gonzales RJ, Krause DN, Duckles SP: Effect of estrogen on cerebrovascular prostaglandins is amplified in mice with dysfunctional NOS. Am J Physiol Heart Circ Physiol 2004;287:H588-H594.
73. Egan KM, Lawson JA, Fries S, et al: COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004;306:1954-1957.
74. Sullivan JC, Sasser JM, Pollock DM, Pollock JS: Sexual dimorphism in renal production of prostanoids in spontaneously hypertensive rats. Hypertension 2005;45:406-411.
75. Hennan JK, Huang J, Barrett TD, et al: Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001;104:820-825.
76. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A: Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004;109:3000-3006.
77. Mamdani M, Rochon P, Juurlink DN, et al: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-486.
78. Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
79. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-2029.
80. Solomon DH, Schneeweiss S, Glynn RJ, et al: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-2073.
81. European Medicines Agency: Questions and answers on celcoxib/Cox-2 inhibitors. EMEA/214027/2004, http://www.cbg-meb.nl/nl/docs/nieuws/qa-celecoxib. pdf.
82. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
83. White WB, Faich G, Borer JS, Makuch RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003;92:411-418.
84. FitzGerald GA: Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002;89:26D-32D.
85. Ott E, Nussmeier NA, Duke PC, et al: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-1492.
86. Nussmeier NA, Whelton AA, Brown MT, et al: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091.
87. White WB, Strand V, Roberts R, Whelton A: Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004;11:244-250.
88. Farkouh ME, Kirshner H, Harrington RA, et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-684.
89. Pallay RM, Seger W, Adler JL, et al: Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol 2004;33:257-266.
90. Coulter DM, Clark DW: Disturbance of vision by COX-2 inhibitors. Expert Opin Drug Saf 2004;3:607-614.
91. LeLorier J, Bombardier C, Burgess E, et al: Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. Can J Cardiol 2002;18:1301-1308.
92. Sandhu GK, Heyneman CA: Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother 2004;38:700-704.
93. Linton MF, Fazio S: Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 2004;4:116-123.
94. Rabausch K, Bretschneider E, Sarbia M, et al: Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 2005;96:e1-e6.
95. Radomski MW, Palmer RM, Moncada S: The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639-646.
96. Choi HK, Seeger JD, Kuntz KM: Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. Am J Med 2004;116:621-629.